Skip to main content

Market Overview

Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose

Share:
Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose
  • The FDA has accepted for review Adamis Pharmaceuticals Corporation's (NASDAQ: ADMP) marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose.
  • The agency's target action date is November 12.
  • The company resubmitted the application in May after it received a complete response letter in November 2020.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: ADMP shares are up 11.9% at $1.13 during the premarket session on the last check Wednesday.
 

Related Articles (ADMP)

View Comments and Join the Discussion!

Posted-In: Briefs OpioidsBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com